Monday, February 16, 2026
Cortexa Therapeutics Advances Target Validation as Phase 1b and Phase 2 Research Progress
FOR IMMEDIATE RELEASE Cortexa Therapeutics Advances Target Validation as Phase 1b and Phase 2 Research Progress Phoenix, Arizona – February 16, 2026 – Cortexa Therapeutics, Inc. today announced significant progress in its scientific validation roadmap, with Phase 1b and Phase 2 studies currently underway in collaboration with its contract research organization (CRO) partner in Scotland. These phases represent a critical advancement in validating Cortexa’s biological target and strengthening the
